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Direct interactions between the genes that regulate
development and those which regulate the cell cycle
would provide a mechanism by which numerous bio-
logical events could be better understood. We have
identified a direct role for PAX5 in the control of p53
transcription. In primary human diffuse astrocytomas,
PAX5 expression inversely correlated with p53 expres-
sion. The human p53 gene harbours a PAX binding
site within its untranslated first exon that is conserved
throughout evolution. PAX5 and its paralogues PAX2
and PAX8 are capable of inhibiting both the p53 pro-
moter and transactivation of a p53-responsive reporter
in cell culture. Mutation of the identified binding site
eliminates PAX protein binding in vitro and renders the
promoter inactive in cells. These data suggest that PAX
proteins might regulate p53 expression during develop-
ment and propose a novel alternative mechanism for
tumour initiation or progression, by which loss of p53
function occurs at the transcriptional level.
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Introduction
One aim of genes that are involved in controlling develop-
mental processes is to influence the cell cycle in time and
space. By manipulating the cell cycle, developmental regu-
latory genes direct cellular growth and differentiation, and
thus permit embryogenesis to proceed in an exquisitely
controlled manner. Such genes are also likely candidates
for involvement in oncogenesis, owing to their effects on
cell growth.
Pax genes encode nuclear transcription factors which
have been implicated in the control of mammalian develop-
ment (Gruss and Walther, 1992; Chalepakis et al., 1993;
Stuart et al., 1994). Thus far, nine mammalian Pax genes
have been identified (Stapelton et al., 1993). All PAX
proteins contain a conserved DNA binding motif termed the
paired box. In addition, some contain a full homeodomain
(PAX3, 7,4 and 6) whereas others contain a partial homeo-
domain (PAX2, 5 and 8) and yet others none at all (PAX1
and 9). Mutations within Pax genes have been demonstrated
to be involved in three mouse developmental mutants and
two corresponding human syndromes (Chalepakis et al.,
1993; Stuart etal., 1994). During development ofthe central
nervous system, PAX2, 5 and 8 are most highly expressed
in the ventricular zone. In addition, PAX5 is an important
regulator of B cell development and its mutation arrests B
cells at an early stage ofdevelopment (Barberis et al., 1990;
Adams et al., 1992; Urbanek et al., 1994). Murine Pax genes
have been shown to act as proto-oncogenes as they are
able to transform cells in culture which subsequently form
tumours in nude mice (Maulbecker and Gruss, 1993).
Recently, a number ofhuman Pax genes have been implica-
ted in various types ofcancer-Pax5 in astrocytomas (Stuart
et al., 1995), Pax2 and 8 in Wilms' tumour (Dressler and
Douglass, 1992; Poleev et al., 1992) and Pax3 and 7 in
rhabdomyosarcoma (Barr et al., 1993; Galili et al., 1993;
Shapiro et al., 1993; Davis et al., 1994).
The p53 tumour suppressor gene encodes a nuclear tran-
scription factor and is the most commonly mutated gene in
human cancer thus far identified (Oren, 1992; Donehower
and Bradley, 1993). These mutations commonly occur in its
DNA binding domain, rendering it unable to transactivate
its target genes (Prives, 1994). p53 appears to control the
cell cycle by arresting cells in late GI phase by activating
downstream target genes, notably WAFJ (El-Deiry et al.,
1993). In addition to its role in the cell cycle, p53 has been
demonstrated to mediate apoptosis in a variety of cell types
(Oren, 1994). Studies involving the control of expression
of p53 itself have so far provided only limited insight into
the transcriptional regulation of the p53 gene (Zambetti
et al., 1992; Deffie et al., 1993). In contrast, the p53 protein
appears to be regulated exquisitely by a variety of mechan-
isms which affect its quantity as well as its function
(Momand et al., 1992; Oliner et al., 1992; Zauberman et al.,
1993) and also by viral proteins (Zambetti et al., 1992;
Levine, 1993a,b).
The role of p53 in developmental processes has not been
studied extensively, although it appears to undergo temporal
and spatial changes in expression during prenatal develop-
ment (Rogel et al., 1985; Schmid et al., 1991).
In this report, we demonstrate that one class of PAX
proteins is capable of inhibiting human p53 expression by
direct DNA binding of the PAX protein to a sequence in the
5' region of the p53 gene. In addition, mutational analysis
ofthePAX binding site revealed that it is absolutely required
for basal promoter activity, suggesting that PAX proteins
may bind to this site and physically impede an as yet
unidentified positive regulatory factor transactivating the
promoter. We discuss potential implications of these results
for oncogenesis and we present a model for PAX-mediated
regulation of the cell cycle and of specific differentiation
events during embryonic development.
Results
PAX5 expression in human astrocytomas
We have previously demonstrated a positive correlation
between PAX5 expression and the level of malignancy in
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Fig. 1. PAX5 mRNA expression inversely correlates with mutant p53
protein in primary human astrocytomas. In the left panel, no PAX5
expression was detected in a medium grade (WHO grade III)
anaplastic astrocytoma (B) and p53 was abundantly expressed (C). In
the right panel, a representative glioblastoma multiforme (WHO grade
IV), PAX5 was focally expressed (E) and p53 was not expressed
(arrow) (F). Tumour identification numbers in the top left of each
phase contrast panel correspond to those previously described (Stuart
etal., 1995).
human astrocytic tumours (Stuart et al., 1995). In all
cases, expression of PAX5 coincided with that of various
oncogenes; however, when double labelling experiments
were performed for PAX5 mRNA and p53 protein (PAb
240), it was evident that in low-grade astrocytomas where
PAX5 was not expressed, p53 was highly expressed. While
not formally proven, this overexpressed p53 is likely to
be mutant. Alternatively, in highly malignant astrocytomas
(glioblastoma multiforme), those areas which abundantly
expressed PAX5 were consistently p53 negative (Figure
1 and data not shown). This observation appears to be
specific for tumours which express PAX5, as a non-diffuse
astrocytoma not expressing PAX5 but expressing PAX4
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Fig. 2. PAX protein expression inhibits p53-mediated transactivation in
transiently transfected NIH 3T3 cells. PAX 2, 5 and 8 decrease
reporter activity, whereas other PAX proteins (which do or do not
contain a homeodomain) are unable to do so.
did not show a negative correlation between PAX4 and
p53 (data not shown). As the stability of mutant p53
protein is typically much greater than that of wild-type
p53, we cannot rule out the possibility that wild-type p53
was present but not detectable in tumour cells over-
expressing PAX5. However, our data raised the possibility
that PAX5 may influence p53 expression or function,
either directly or indirectly.
PAX2, 5 and 8 modulate p53-dependent reporter
activity
In an attempt to investigate a possible relationship between
PAX5 and p53, we studied the effect of PAX proteins on
the activity of endogenous p53 in cell culture. To that
end, NIH 3T3 mouse fibroblasts were co-transfected with
the RGC-CAT reporter plasmid which contains multiple
copies of a p53 binding sequence in front of the chloram-
phenicol acetyl transferase (CAT) gene together with
various PAX expression plasmids. Figure 2 shows that
PAX5 had a pronounced inhibitory effect on p53-
dependent reporter activity. A comparable inhibitory effect
was also exerted by PAX2 and PAX8, both of which share
substantial sequence and structural similarity with PAX5
(Stuart et al., 1994). PAX1 and PAX6 expression had a
partial inhibitory effect, whereas PAX3 did not affect the
transcriptional activity of p53 at all. Variations in the
relative inhibitory effect of each PAX were observed, yet
the overall pattern emerging from multiple transfections
is consistent with the data presented in the figure shown.
As a control, an unrelated promoter-reporter construct
(TK-CAT), which contains the thymidine kinase promoter
linked to CAT, was employed to test whether the reduction
in reporter activity was due to PAX-induced transcriptional









absence of the various PAX expression plasmids (data not
shown). These data indicate that, as suggested from the
expression patterns of PAX5 and p53 in tumour cells,
there is indeed a relationship between the two proteins.
More specifically, the data show that PAX5, as well as
the related PAX2 and PAX8 proteins, can markedly reduce
the cellular levels of functional p53.
PAX proteins bind to a sequence within exon 1 of
p53
To investigate whether the inverse correlation between
PAX protein expression and levels of functional p53 could
be due to a direct inhibition of p53 transcription, we first
analysed the 5' region of the human p53 gene for PAX
binding sites. This region may be divided into three
distinct elements: a stretch of -250 bp upstream of exon
1 contains promoter activity (Tuck and Crawford, 1989),
exon 1 and a large (10 kb) intron which harbours a strong
but unrelated promoter in its first 1.2 kb (Reisman et al.,
1988). The p53 promoter, exon 1 and 1.2 kb 3' of intron
1 were analysed for PAX binding sites by electrophoretic
mobility shift assays (EMSAs). A single PAX binding site
was identified which resides at the 3' end of exon 1
between nucleotides +166 and +216 [+1 refers to the
transcriptional start site, as previously defined (Tuck and
Crawford, 1989)]. This binding site (Figures 3B and 4A)
contains the PAX core motif GTYMC as well as the CA
dinucleotide previously identified in PAX5 binding sites
(Czerny et al., 1993). Figure 3A shows binding of various
PAX proteins to this sequence. PAX2, 5 and 8 bound most
efficiently to this site, PAXI and 6 exhibited relatively
weaker binding, whereas PAX3 did not bind at all. The
presence of a partial homeodomain in PAX2, 5 and 8 may
be important for efficient binding, as two deletion mutants,
PaxA3 (similar to the murine splotch Pax3) and PaxA6
(similar to the small eye Pax6), which contain only the
paired domain, display greater binding to this sequence
than their wild-type counterparts which contain a full
homeodomain.
The sequence of the PAX binding site identified in the
EMSA is highly conserved between mouse, rat and man
(Figure 3B), supporting the functional significance of
this site.
To characterize the PAX binding site further, we sub-
jected it to mutational analysis (Figure 4A). Point mutation
of the C within the CA dinucleotide did not affect binding;
nor did mutation 4 (data not shown). By contrast, mutations
2 and 3, introduced within the PAX core motif, significantly
reduced binding of all PAX proteins (Figure 4B).
PAX2, 5 and 8 inhibit the activity of the isolated
p53 promoter in cell culture
PAX proteins bind to a sequence within the first exon of
the human p53 gene, and PAX2, 5 and 8 are capable of
strongly decreasing p53 protein function in cell culture.
These observations proposed a mechanism whereby PAX
proteins may exert their inhibitory effect on p53 function
by directly repressing the transcription of the p53 gene
itself. We therefore constructed a reporter plasmid,
pS3LUC, which contains a 490 bp genomic fragment
comprising the p53 promoter and exon 1, in front of the
firefly luciferase gene (Figure SA, upper panel). This
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Fig. 3. PAX proteins bind to a sequence within the 3' end of exon 1
of the human p53 gene. (A) EMSA was performed as described in
Materials and methods. PAX2, 5 and 8 bind to a similar extent, PAXI
and 6 bind less efficiently and PAX3 not at all. PAXA3 and PAXA6
represent truncated proteins consisting of the paired domain only (see
text). The PAX3 paired domain alone is able to bind weakly, whereas
the PAX6 paired domain alone binds very strongly. (B) Evolutionary
comparison of the sequence surrounding the PAX binding site within
the first exon of the mouse, rat and human p53 genes. Sequences are
from Bienz-Tadmor et al. (1985). In the mouse and rat, the GTCAC
motif is located on the sense strand, whereas the human GTCAC motif
is located on the antisense strand. Numbers refer to the nucleotide
position according to Tuck and Crawford (1989).
sion plasmids into primary rat embryo fibroblasts and
reporter activity was assayed (Figure 5A, lower panel). It
is evident that PAX2, 5 and 8 virtually abolish p53
promoter activity. The inhibition of this p53 promoter
construct by overexpression of PAX proteins argues
strongly in favour of the contention that PAX proteins can
serve as negative regulators of p53 expression, presumably
through sequence-specific DNA binding to a cognate
regulatory element in the p53 gene.
Point mutation of the p53 promoter abolished
transcriptional activity
To test whether the PAX binding site is an absolute
requirement for transcriptional inhibition, we generated
pS3mutLUC (Figure SB, upper panel). This reporter con-
struct is identical to the wild-type p53 promoter-luciferase
construct, with the exception of a single point mutation
in the PAX binding site core motif previously found to
virtually eliminate PAX binding (Figure 4A). Surprisingly,
all promoter activity was totally ablated when this construct
was transfected into a number of cell types, including
NIH 3T3 and primary rat embryo fibroblasts (Figure SB,
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Fig. 4. (A) Point mutation of the pentanucleotide within the PAX binding site abrogates PAX protein binding in vitro. Oligonucleotides containing
the point mutations shown (M1-M4) were synthesized and EMSA were performed as described in Materials and methods. The relative binding of
PAX proteins was measured by phosphorimagery. (B) Point mutations within the pentanucleotide significantly reduce PAX protein binding. EMSA
were performed and exposed to X-ray film for times similar to those shown in Figure 3.
lower panel). We conclude that the PAX binding site is
also required for basal promoter activity. In support of
this conclusion, deletion analysis of the p53 promoter and
exon 1, from either the 5' or 3' end, demonstrated that
only the most 3' 85 bp of exon 1 were essential for
promoter activity (Tuck and Crawford, 1989). Further-
more, the sequence directly 3' to the PAX pentanucleotide
core binding sequence is highly conserved between mouse,
rat and human (Bienz-Tadmor et al., 1985). This sequence,
CACGCTTCCC, shows high homology to the consensus
binding sequence for TFII-I, a regulator of basal transcrip-
tion (Roy et al., 1991). Our present data demonstrate that
the cytosine at position +204 is a key determinant of this
promoter activity. Presumably it constitutes a base contact
for a factor governing p53 promoter activity. The import-
ance of this cytosine to both PAX binding and promoter
activity strongly suggests that PAX proteins target directly
a DNA element which is essential for the activity of the
p53 promoter. Such PAX-DNA interaction is likely to
underlie the repression of p53 promoter activity by PAX5
and its relatives.
Discussion
We have demonstrated that PAX5 and its relatives are
capable of inhibiting the function of p53. The mechanism
by which this inhibition occurs is likely to involve PAX
protein-DNA interactions at a site which is located close
to one which is responsible for basal promoter activity.
Implications for developmental mechanisms
The identification of p53 as a downstream target gene for
PAX proteins leads to the possibility of explaining some
questions regarding the mechanism of action of PAX2, 5
and 8 during embryonic development. A theoretical model
for PAX-p53 functional interactions is presented in Figure
6. In this theory, we propose the following mechanism of
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Fig. 5. (A) PAX proteins abolish activity of the human p53 promoter in transiently transfected primary rat embryo fibroblasts (mean + SEM, n = 5
independent transfections). Upper panel, plasmid map of p53LUC showing the wild-type pentanucleotide of the PAX binding site. Lower panel, the
cells were transfected with p53LUC (2 ,ug) and PAX expression plasmids (200 ng) or parental pCMV vector (CONTROL) by calcium phosphate
precipitation. An unrelated promoter, RSVLUC (2 .tg) was unaffected by PAX5 expression. (B) Point mutation abolishes activity of the human p53
promoter in transiently transfected NIH 3T3 and primary rat embryo fibroblasts (mean + SEM, n = 3 independent transfections). Upper panel,
plasmid map of p53mutLUC showing the mutated pentanucleotide of the PAX binding site. Lower panel, the cells were transfected with the reporter
plasmids (2 tg) in parallel by calcium phosphate precipitation.
is determined and represents the 'stem cell' population
for that organ or tissue. For proper development of
that tissue, a precise combination of growth factors,
transcription factors and other genes are required to guide
the population along the proper pathway. In our model,
we assume that a positive growth signal is presented to
the cell. The positive growth signal activates Pax gene
expression and the corresponding proteins cause a tran-
scriptional inhibition of p53. This scenario continues until
the signal is no longer sufficient to sustain Pax gene
activation and the gene is transcriptionally inactivated. In
the absence of PAX, the inhibition of p53 is alleviated
and p53 is again able to be transcribed.
The functional implications of this model are that,
during the initial phases, p53 is active and may help in
determining the fate of the cell population. However, once
the cell population is determined, a rapid growth of these
(still undifferentiated) cells is required so that a large mass
of cells is attained prior to differentiation. Pax genes, in
part, mediate this rapid expansion. Once a 'critical mass'
is obtained, PAX is no longer expressed and p53 is
expressed.
The developing central nervous system is highly com-
plex, requiring precise interactions between different cell
types and fine control of cellular growth and differentiation
rates so that the many different structures can be formed.
PAX5 is expressed before differentiation in the cells which
migrate from the ventricular zone to the intermediate zone
of the neural tube (Asano and Gruss, 1992). The ventricular
zone is characterized by its high mitotic rate prior to
cellular differentiation. Upon cell differentiation, expres-
sion of PAX2, 5 and 8 ceases-unlike PAX3 which
continues to be expressed in differentiated cells. Thus,
inhibition of p53 in PAX5-expressing cells would agree
with the highly proliferative and undifferentiated pheno-
type of these cells.
Recently, mutation of the murine PaxS gene has been
described (Urbanek et al., 1994). The homozygous mice
display a number of phenotypes which include a complete
block in early B cell differentiation. B cell differentiation
proceeds along a well documented path from stem cells
to the immunoglobulin-secreting plasma cells (for reviews,
see Rolink and Melchers, 1991; Kantor and Herzenberg,
1993; Hagman and Grosschedl, 1994). PAX5 is expressed
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Fig. 6. Theoretical model for the involvement of PAX-mediated
temporal down-regulation of the p53 gene during embryonic
development.
during the early stages of B cell differentiation, i.e. up to
the mature B cell stage and, in the later blast and plasma
cell stages, PAXS expression is no longer detectable
(Barberis et al., 1990; Adams et al., 1992). However, in
PaxS mutant mice, B cell differentiation is arrested in the
early pro-B cell stage, with the cells displaying CD45
expression (which is normally lost during later differentia-
tion stages) and the cells being morphologically different
from the corresponding wild-type cells which undergo
normal differentiation (Urbanek et al., 1994). One feature
of B cell differentiation is a selection at the mature B
cell/blast stage prior to plasma cell genesis. This selective
period determines which cells will progress through to
plasma cells and which will undergo apoptosis (Rolink
and Melchers, 1991). The mechanisms which underlie the
apoptotic death of B cells are partly understood at present.
bcl-2 prevents apoptosis selectively in B cells (Vaux et al.,
1988; McDonnell et al., 1989; Henderson et al., 1991)
and the bax gene encodes a protein which has opposite
physiological functions (Miyashita and Reed, 1995). Both
of these genes are potentially controlled by p53 (Miyashita
et al., 1994a,b; Miyashita and Reed, 1995). Therefore, it
is conceivable that p53 is involved in B cell apoptosis.
PAX5 expression would inhibit p53, the consequences of
which would be an inhibition of BAX and continued
expression of Bcl-2. Such a scenario would agree both
with our observations and those of the Pax5 mutant mice.
We envisage that expression of PAX5 early in pro-B cell
differentiation is required to inhibit p53 expression, leading
to a rapid growth and partial differentiation phase during
which complete differentiation is not permitted and, prob-
ably more importantly, the cellular decisions concerning
apoptosis are prevented. Once PAXS expression is reduced,
p53 expression commences and the final stages of differen-
tiation occur. In the absence of PAX5, the myriad of
molecular mechanisms which it controls are deregulated
and, in particular, p53 is active in the early phases during
which it would otherwise not be active.
Implications for cancer
Inactivation of p53 is an extremely common event in
human cancer (Levine et al., 1991; Fults et al., 1992).
However, with the exception of functional inactivation of
the p53 protein by either viral proteins (Ludlow, 1993) or
the product of the MDM2 gene (Momand et al., 1992;
Oliner et al., 1992), all previously reported examples of
p53 inactivation in human tumours have been due to
mutations within the p53 gene or gross chromosomal
rearrangements involving the p53 locus. The effect of
mutating p53 has been studied widely and results in
compromised sequence-specific DNA binding and tran-
scriptional activity (Oren, 1992; Donehower and Bradley,
1993). Thus, the commonly encountered p53 mutations
eliminate the normal tumour suppressor function of p53
by producing a functionally deficient protein. Our results
indicate the existence of a novel mechanism for loss of
p53 activity, namely the inhibition of p53 gene expression
by PAX proteins. The constitutive expression of PAX5 or
a related protein would thus bypass the need for p53
mutation to abrogate p53-mediated processes. Cancer is a
multi-step process, which requires the cumulative effects
altering both positive and negative regulators of cell
proliferation and cell survival (Nowell, 1986; Vogelstein
and Kinzler, 1993). Abrogation of p53 transcription by
PAX may serve as an important factor in this multi-step
process. In addition, it is conceivable that inappropriate
PAX expression may contribute to tumorigenesis by
activating specific target genes, as well as by inactivating
other inhibitory genes in addition to p53.
Progression of a tumour to a higher state of malignancy
is one of the most important aspects of cancer. Many
tumours start as low malignancy neoplasms which, even
after conventional treatment, progress to higher forms of
malignancy. These often harbour metastatic potential
which grossly alters patient prognosis. Our initial observa-
tion demonstrated that PAXS is overexpressed in highly
malignant glioblastoma multiform tumours, whereas
tumours of lower malignancy (anaplastic astrocytomas,
astrocytomas) did not express significant levels of PAXS
(Stuart et al., 1995). We surmised that PAX5 may play a
role in progression of the tumour, and its ability to inhibit
p53 concurs with this. It is of note that if a mutant form
of p53 was already present in the tumour cell and the
promoter was not mutated, then PAX5 would also inhibit
expression of this mutant p53. However, it is conceivable
that p53 is only one of a set of PAX5 target genes whose
activation or inhibition may combine to provide the cancer
cell with a positive growth advantage. Thus, even in cells
which have already lost wild-type p53 function owing to
prior p53 gene alterations, the activation of PAXS will
probably have a net selective advantage.
Another tumour which may potentially relate to these
observations is Wilms' tumour (nephroblastoma), a
pediatric renal tumour affecting 1 in 10 000 children (for
review, see Hastie, 1994). Phenotypically, Wilms' tumour











that have failed to undergo transformation to the epithelial
components of the kidney. PAX2 and 8 are persistently
expressed in Wilms' tumour, in contrast to their normal
temporally regulated expression pattern in the un-
differentiated developing kidney prior to the mesenchyme-
epithelium transformation (Dressler and D,ouglass, 1992;
Eccles et al., 1992; Poleev et al., 1992). The status of
p53 has not been studied widely in Wilms' tumour,
although it has been reported that in vitro the Wilms'
tumour suppressor gene product WT1 can form a transcrip-
tionally active complex with wild-type p53 and that p53
is mutated in a small subset of Wilms' tumours (Hastie,
1994). In view of the negative effects of PAX2 and 8 on
p53, comparable with those of PAX5, it is tempting to
speculate that the aberrant expression of these proteins in
Wilms' tumour may also contribute to malignancy by
compromising p53 function.
In conclusion, we have demonstrated a role for regu-
lators of development in directing the cell cycle to allow
the proper development of the embryo. In addition,
reactivation of these pathways later in life may constitute




PAX cDNAs were cloned into pCMV expression plasmids and have
been described previously (Maulbecker and Gruss, 1993). RGC-CAT
contains multiple copies of a p53 binding sequence located near the
ribosomal gene cluster in front of the CAT gene (Kern et al., 1991).
The p53LUC plasmid was made using PCR. A 4 kb EcoRI human
genomic DNA fragment cloned into pBR322 was used as a template
and PCR was performed with the following primers (from 5' to
3'): sense, TTGAGCTCAGGATCCAGCTGAGAGCAAA; antisense,
TTCTCGAGAATCCAGGGAAGCGTGTCACCGT.
PCR was performed in 10 mM Tris-HCl pH 8.85, 25 mM KCI, 5 mM
(NH2)2SO4, 2 mM MgSO4 with 10 ng of DNA template, 0.1 jIg of each
primer and PWO polymerase (2.5 U) in a final volume of 100 pl.
PCR was performed in an automated thermocycler (Biometra trio-
thermoblock) and consisted of 30 cycles of denaturation at 95°C,
annealing at 60°C and extension at 72°C. The PCR products were
purified over spin columns (Qiagen), digested with BamHI and XhoI
and ligated into pBluescript and subsequently sequenced. Once the
sequence was verified, the plasmid was digested with Sacl and XhoI and
the insert subcloned into pGL-2 basic (Promega). Point mutation of the
PAX binding site was performed as above using the antisense primer:
5'-TTCTCGAGAATCCAGGGAAGCGTTTCACCGT-3'. This point
mutation introduces a novel XmnI restriction site which was used to
screen colonies. Those colonies which displayed the correct digestion
pattern were sequenced. Once the sequence was verified, the plasmid
was digested with Sacl and XhoI and the mutated insert was subcloned
into pGL-2 basic.
Oligonucleotides
50mer oligonucleotides corresponding to all potential binding sites within
the p53 promoter, exon 1 and 1.2 kb of the first intron as well as all
point mutants used were synthesized on a BIOSEARCH 8700 DNA
synthesizer and purified subsequently by HPLC. Double-stranded oligo-
nucleotides were labelled with [32P]dCTP (Amersham, UK).
Preparation of whole cell extracts and electrophoretic
mobility shift assays
COS-7 cell extracts were prepared and EMSA performed as previously
described (Chalepakis et al., 1991). Briefly, COS-7 cells were transfected
with 10 jig of the expression vectors [pCMV, pCMV(+)PAXI,
pCMV(+)PAX2, pCMV(+)PAX3, pCMV(+)PAX5, pCMV(+)PAX6,
pCMV(+)PAX8] using the calcium phosphate precipitation technique.
Cells were harvested after 72 h and resuspended in 200 id of extraction
buffer [20 mM HEPES, 150 mM NaCl, 25% glycerol, 0.5 mM dithio-
threitol (DTT) and protease inhibitors]. Cell suspensions were sonicated
(Branson cell disruptor), the resulting mixture centrifuged and the
supernatant frozen and stored at -80°C.
EMSAs were performed with the COS-7 extracts in a 15 jil volume
containing 15 mM Tris-HCl (pH 7.5), 6.5% glycerol, 0.7 mM EDTA,
0.2 mM DTT, 90 mM KCI, 1 mg/ml bovine serum albumin, 100 ng of
sonicated salmon sperm DNA and 15 fmol of labelled oligonucleotides.
Protein-DNA complexes were allowed to form by incubation at room
temperature for 30 min, and free DNA or protein-DNA complexes were
resolved on 5% polyacrylamide gels in 0.5% TBE. Gels were dried and
exposed to Kodak X-OMAT film at -80°C.
Cell culture and DNA transfection
All cell lines were cultured in DMEM (Gibco BRL) supplemented with
10% fetal calf serum (Boehringer Mannnheim). DNA transfections were
performed in 60 mm tissue culture dishes using the calcium phosphate
precipitation technique. Medium was changed 3 h before the addition
of the precipitate. Twelve to 15 h after addition of the precipitate, the
medium was removed, cells were washed three times with phosphate-
buffered saline (PBS) and fresh medium added. Cells were harvested
48 h after addition of the precipitate.
Reporter plasmid assays
CAT activity was assayed according to Gorman et al. (1982). Cells were
washed three times in PBS, harvested in 40 mM Tris-HCI pH 7.5, 1 mM
EDTA, 150 mM NaCl, resuspended in 150 jl of 250 mM Tris-HCI
pH 7.8 and lysed by freeze-thaw in liquid nitrogen at 370C. Endogenous
acetylases were inactivated by heating the lysed cells at 60°C for 7 min
and the extracts cleared by centrifugation (12 000 g, 10 min at 4°C).
Cell extracts were stored at
-20°C until assayed. Fifty microlitres of
extract were added to 105 jil of 250 mM Tris-HCI pH 7.8 and 0.125 jCi
of [14C]chloramphenicol and incubated at 37°C for 5 min. Twenty
microlitres of 4 mM acetyl coenzyme A were added and the mixture
incubated at 37°C for a further 30 min. The mixture was then extracted
with 600 jl of ethyl acetate and centrifuged for 60 s. The ethyl acetate
phase was removed, dried in a Speedvac and the pellet resuspended in
8 jl of ethyl acetate and dotted onto thin-layer chromatography (TLC)
plates (Polygram SIL-G, Machery-Nagel). TLC was performed in a
95%:5% chloroform:methanol solution for -60 min. TLC plates were
exposed to Kodak X-OMAT film for 12 h at -80°C.
To assay luciferase activity, cells were washed three times in PBS,
harvested in PBS, pelleted by centrifugation and directly lysed in 25 mM
Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane
N,N,N',N'-tetraacetic acid, 10% glycerol and 1% Triton X-100.
Luciferase assays were performed in 20 mM tricine, 1.07 mM
(MgCO3)4Mg(OH)2-5H20, 2.67 mM MgSO3, 0.1 mM EDTA, 33.3 mM
DTT, 270 jiM coenzyme A, 470 jM luciferin and 530 jM ATP. Assays
were performed either in a Turner designs model 20 luminometer or a
Berthold Lumat LB 9501 luminometer.
Antibodies
Monoclonal mouse antibodies (Pab 240) against mutant p53 (Oncogene
Science) were used at dilutions of 1:100. Detection antibodies: 5(6)-
carboxy-fluorescein-N-hydroxysuccinimide ester (FITC) conjugated to
anti-digoxigenin sheep F(ab)' fragments (Boehringer Mannheim), tetra-
methylrhodamine (TRITC) conjugated to goat antibody against rabbit
IgG (Sigma) were used at 1:100 dilution. Cy3 conjugated to goat anti-
mouse IgG [F(ab)2 fragments] (Dianova) was used at 1:500 dilution.
In situ hybridization-immunohistochemistry
Sections (13 gm) were cut with a cryostat at -20°C and transferred onto
slides subbed with gelatine and chromalum. Sections were dried at 37°C,
fixed for 20 min with 4% paraformaldehyde and rinsed in PBS. Sections
were pre-hybridized (200 ji per slide) with 5x SSC, 5x Denhardt's,
50% deionized formamide, 250 ,ug/ml of yeast tRNA, 250 jg/ml of
denatured salmon sperm DNA and 4 mM EDTA, for 2-3 h in a humid
45°C chamber, and washed at room temperature for 2 min in 70, 90 and
100% ethanol. Digoxigenin-labelled RNA probes were synthesized,
using T7 or T3 polymerase according to the supplier's directions
(Boehringer Mannheim) from the linearized plasmid cDNA clone
described above. Sections were incubated as above (with probe) in pre-
hybridization buffer lacking salmon sperm DNA (2.5 ng/jil), and washed
twice for 15 min with 2x SSC, 15 min with 0.2X SSC and twice for
15 min with 0.1 x SSC at 45°C. For double-labelling fluorescence, cells
were incubated with primary antibodies for 2 h at room temperature,
rinsed, and both secondary antibodies applied for 2 h. Controls were:
(i) using sense probe; (ii) omitting the probe, first antibody, second
antibody or all of the above. Immunofluorescence stained preparations
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were viewed with a Zeiss Axiophot photomicroscope with phase contrast
corresponding to the appropriate magnification.
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